Cargando…

Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening

BACKGROUND: Drug repurposing for cancer treatment is an emerging approach to discover clinically approved drugs that demonstrate antineoplastic effect. The effective therapeutics for patients with advanced adrenocortical carcinoma(ACC) are greatly needed. The objective of this study was to identify...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilubol, Naris, Zhang, Lisa, Shen, Min, Zhang, Ya-Qin, He, Mei, Austin, Christopher P, Kebebew, Electron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493320/ https://www.ncbi.nlm.nih.gov/pubmed/22999104 http://dx.doi.org/10.1186/1479-5876-10-198

Ejemplares similares

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
por: Tirosh, Amit, et al.
Publicado: (2019)

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
por: Nilubol, Naris, et al.
Publicado: (2018)

Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer
por: Michael, Nicholas, et al.
Publicado: (2022)

SAT-568 Glutamine Metabolism Is a New Potential Therapeutic Target in Aggressive Thyroid Cancer
por: Patel, Dhaval, et al.
Publicado: (2019)

Adrenocortical Carcinoma and Synchronous Malignancies
por: Guerrero, Marlon A., et al.
Publicado: (2010)

Current Status and Future Targeted Therapy in Adrenocortical Cancer
por: Alyateem, George, et al.
Publicado: (2021)

RF07 | PSUN356 Synergistic Combination of HSP90 and PI3K inhibitors in Adrenocortical Cancer
por: Mishra, Prachi, et al.
Publicado: (2022)

Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors
por: Gara, Sudheer Kumar, et al.
Publicado: (2018)

Adrenocortical carcinoma and pulmonary embolism from tumoral extension
por: Shekhar, Skand, et al.
Publicado: (2019)

Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III)
por: Thakur, Shilpa, et al.
Publicado: (2019)

Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples
por: Gara, Sudheer Kumar, et al.
Publicado: (2015)

Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
por: Neychev, Vladimir, et al.
Publicado: (2015)

68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
por: Shell, Jasmine, et al.
Publicado: (2018)

SUN-115 Distinct DNA Methylation Signature in Neuroendocrine Tumors of Different Primary Sites and Hereditary Predisposition
por: Tirosh, Amit, et al.
Publicado: (2020)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

MiR-20a Is Upregulated in Anaplastic Thyroid Cancer and Targets LIMK1
por: Xiong, Yin, et al.
Publicado: (2014)

RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma
por: Liu-Chittenden, Yi, et al.
Publicado: (2017)

Preclinical Models of Adrenocortical Cancer
por: Sedlack, Andrew J. H., et al.
Publicado: (2023)

GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
por: Gara, Sudheer Kumar, et al.
Publicado: (2020)

Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
por: Zhang, Lisa, et al.
Publicado: (2016)

Editorial: Molecular Mechanisms in Cancer Endocrinology With Clinical Implications
por: Nilubol, Naris
Publicado: (2022)

KIAA0101 Is Overexpressed, and Promotes Growth and Invasion in Adrenal Cancer
por: Jain, Meenu, et al.
Publicado: (2011)

Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
por: Neychev, Vladimir, et al.
Publicado: (2017)

To the editor
por: Kebebew, Electron, et al.
Publicado: (2017)

Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome
por: Boufraqech, Myriem, et al.
Publicado: (2019)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer
por: Xiong, Yin, et al.
Publicado: (2015)

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma
por: Liu-Chittenden, Yi, et al.
Publicado: (2015)

MiR-886-3p Regulates Cell Proliferation and Migration, and Is Dysregulated in Familial Non-Medullary Thyroid Cancer
por: Xiong, Yin, et al.
Publicado: (2011)

New Therapies for Advanced Thyroid Cancer
por: Laha, Diprajan, et al.
Publicado: (2020)

LOX is a novel mitotic spindle-associated protein essential for mitosis
por: Boufraqech, Myriem, et al.
Publicado: (2016)

Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure
por: Libutti, Steven K., et al.
Publicado: (2018)

Alterations of DNA methylation were associated with the rapid growth of cortisol-producing adrenocortical adenoma during pregnancy
por: Wang, Chuan, et al.
Publicado: (2021)

Performance comparison of SNP detection tools with illumina exome sequencing data—an assessment using both family pedigree information and sample-matched SNP array data
por: Yi, Ming, et al.
Publicado: (2014)

Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer
por: Mishra, Prachi, et al.
Publicado: (2021)

The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment
por: Laha, Dipranjan, et al.
Publicado: (2021)

Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma
por: Lerario, Antonio M., et al.
Publicado: (2018)

Biomarkers in Thyroid Tumor Research: New Diagnostic Tools and Potential Targets of Molecular-Based Therapy
por: Gimm, Oliver, et al.
Publicado: (2011)

Editorial: Translational Research in Thyroid Cancer
por: Vasko, Vasyl, et al.
Publicado: (2020)

Is VTE Prophylaxis Necessary on Discharge for Patients Undergoing Adrenalectomy for Cushing Syndrome?
por: Babic, Bruna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f06pgk45k47csgrihe47hk7qmt